Tissue sealants market research report

RITMIR025: Tissue Sealants – A Market Insight Report, July 2013
© RI Technologies - www.researchimpact.com Sample Page - 1
TISSUE SEALANTS MARKET SIZE
Scope of the Study
Tissue Sealants report covers the sources of Sealants and the various applications of tissue sealants in the
market. The Sources of Tissue Sealants covered include Homologous Sealants, Synthetic Sealants and
Autologous Sealants. The applications of Tissue Sealants in Odontology, Cardiology, Neurology, Orthopedics
and Other (such as Urology, Hepatic, Dermatology, etc). The report provides an in depth analysis of each of
the Sources and Applications by their respective categories. The study includes estimates and projections
for the total global Tissue Sealants market and also key regional markets that include North America, Japan,
Europe, Asia-Pacific, Latin America and Rest of World. Estimations and predictions are illustrated
graphically.
Business profiles of 27 major companies are discussed in the report. The report serves as a guide to global
Tissue Sealants industry, covering more than 127 companies that are engaged in tissue sealants R&D and
supply of products and services. Information related to recent product releases, product developments,
partnerships, collaborations, and mergers and acquisitions is also covered in the report.
Tissue Sealants report is an ideal research tool providing strategic business intelligence to the corporate
sector. This report may help strategists, investors, laboratories, pharmaceutical companies, contract
research organizations, and biotechnology companies in –
 Gauging Competitive Intelligence
 Identifying Key Growth Areas and Opportunities
 Understanding Geographic Relevance to Product
 Knowing Regional Market Sizes and Growth Opportunities and Restraints
 Keeping Tab on Emerging Technologies
 Equity Analysis
 Tapping New Markets
Analytics and data presented in this report pertain to several parameters such as –
 Global and Regional Market Sizes, Market Shares, Market Trends
 Product (Global and Regional) Market Sizes, Market Shares, Market Trends
 Technology Trends
 Corporate Intelligence
 Key Companies By Sales, Brands, Products
 Consumer Behavioral Patterns
 Other Strategic Business Affecting Data

Research Methodology
RI Technologies publishes business intelligence reports by going through a cycle of diligent research and
analysis activity. Research is done using both online and offline resources. The study outline of this report is
sketched on the following lines – Global Value Market Estimations & Predictions (2005 -2015), regional
market analysis, product segmentation, global and regional market analysis by product segment, market
trends, M&A, R&D, competitive landscape, technology trends, and other key drivers. Current data helps in
analyzing the future of the industry and is also helpful for doing market evaluations, and estimating the
market size for the future.
This report is uniquely researched and the methodology includes:
 Need and Scope of Study
 Product Definitions
 Segmental Analysis
 Regional Analysis
 Exclusive Data Analytics
 Corporate Intelligence
 Feedback
Right from concept to final compilation of this report, both primary and secondary research methods are
applied. We have provided exclusive feedback forms/pre-release questionnaires for this report to use the
information for authentication of our own findings. Secondary research includes government publications,
investment research reports, web based surveys, website information of both companies and markets, and
other offline resources such as print publications and CDs.
Our compilation of easy to navigate PDF reports are essential value addition resources for leading and
growing companies.

II. REPORT SYNOPSIS
The sealing of the wounds and skin openings after surgery can be done in a compact manner with the help
of tapes and sutures which reduce the rate of contamination of the injured regions by waste materials and
infectious organisms. The other important advantage is that the use of tapes and sutures will reduce the
scar formations to some extent. The major risk with these techniques is the improper application of tapes
and sutures causing complications such as infections, longer time periods of healing of wounds and in some
rare cases even death of the patient because of infections in the tissue resulting in septicemia.
Currently, as an alternative to the above mentioned age old techniques of sealing the wounds and skin
openings due to invasive surgical procedures, hemostats, sealants and glues are being used. Morbidity
associated with infection rates, post‐surgical adhesions, and other specific procedures is reduced to a
considerable extent by the use of hemostats, sealants and glues. Critical surgeries, such as knee
replacement surgery, require the application of tourniquet to control the bleeding. The use of the
tourniquet sometimes results in deep vein thrombosis during the surgery which can be controlled by the
application of hemostats, sealants and glues.
The use of hemostats and sealants during surgeries is both cost effective and time saving. The application
of these substances to the wounds helps the patient to recover faster than the normal methods of suturing
and stapling, thus saving both money and time. The whole surgical process becomes safer and faster.
Mainly, these products are applied to the external wounds. The application and the working of these
products in treating the internal injuries have to be explored extensively.
Application of cyanoacrylate glues for closure of surgical wounds is approved worldwide. The usual process
of closing a small bleeding trauma laceration by suturing includes use of local anesthesia, antibiotic cream
and suture removal kit. The total cost of these products excluding the labor and time is approximately $75.
In contrast, cyanoacrylate products can be applied without anesthetic and without sutures. There is no
need for a removal as cyanoacrylate sloughs off the skin surface. Experiments proved that cyanoacrylate
products have an anti‐microbial property which gave the product an approval by the FDA. This property
also aids in the reduction of the costs to approximately 30% of using sutures. The cost further reduces to
5% of suture cost on inclusion of labor and time to the application of product.
Many of the critical surgeries take longer time as they are to be performed carefully avoiding heavy
bleeding during the surgery. Application of hemostats considerably reduces the time and in turn the cost
(estimated to be $2000 to $10000 per hour) of the surgery as the operation can be done faster than the
expected time because of less hemorrhage during surgery. For example, a $115 hemostat shaves off nearly
4 minutes off the operating time to be cost effective and was proved it could. Based upon the surgical
process hemostats save five to two hours of surgery time.
Use of sealants is not only a cost effective but also an attractive health economic attribute. This was proved
in cases of air leaks occurring after lung resection. Use of normal sutures and staples sometimes result in air
leaks in lung resection patients. Due to this, the patient has to stay for longer periods of time in the hospital
for nearly a month after surgery in the intensive care unit and in some rare cases has to endure another
surgery. Use of sealants completely eliminates air leaks and thus the extra burden in the form of mental
stress, time and expenses on the patient can be reduced effectively. Neurological and spine injuries
sometimes result in leakage of cerebrospinal fluid due to infections like meningitis, severe headaches and

other miscellaneous reasons. In order to avoid the cerebrospinal fluid leaks, the normal process is to close
the dura which is time consuming. Application of proper sealants by efficient surgeons can tackle the
problem of cerebrospinal fluid leakage.
Segmentation of Tissue Sealants Market
Exhibit 1. Segmentation of Tissue Sealants Market by Source and Application
Source Application
Homologous Sealants Odontology
Synthetic Sealants Cardiology
Autologous Sealants Neurology
Orthopedics
*Other
*Other Includes Urology, Hepatic,, Dermatology etc
© RIT, 2013

Global Market Analysis
Global Tissue Sealants market was estimated at US$XX.XX billion in 2012, and is projected to reach US$
XX.XX billion by 2020, growing at a compounded annual growth rate (CAGR) of XX.XX %.
Exhibit 2. Tissue Sealants – Global Value Market Estimations & Predictions (2005 -2020) in US$ Million
Year Value
2005 XX.XX
2006 XX.XX
2007 XX.XX
2008 XX.XX
2009 XX.XX
2010 XX.XX
2011 XX.XX
2012 XX.XX
2013 XX.XX
2014 XX.XX
2015 XX.XX
2016 XX.XX
2017 XX.XX
2018 XX.XX
2019 XX.XX
2020 XX.XX
CAGR% XX.XX
© RIT Figures, 2013
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Million

Synthetic Sealants
Registering a CAGR of XX.XX % during the analysis period, the global market for Synthetic sealants is
projected to be worth US$ XX.XX billion by 2020. The market was estimated at US$ XX.XX million in 2012.
With an estimated market share of about XX.XX % in 2012, North America represents the largest market for
Synthetic sealants with a market of worth US$ XX.XX million. North America is projected to reach US$ XX.XX
million by 2020 by growing at a CAGR of XX.XX % during 2005-2020 to retain the leadership. Asia-Pacific is
expected to be the fastest growing market (CAGR is XX.XX %). while Japan represents second largest market
with a share of XX.XX % in 2010.
Exhibit 3. Synthetic Sealants – Global Value Market Estimations & Predictions (2005 -2020) by Geographic
Regions for North America, Japan, Europe, Asia-Pacific, Latin America and Rest of World in US$ Million
Year/Region North America Japan Europe Asia-Pacific Latin America RoW Total
2005 XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX
CAGR% XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Million
North America Japan Europe Asia-Pacific Latin America RoW

III. MARKET DYNAMICS
Market Overview
Due to the cost advantage and rapid increase in population, Asia-Pacific is the fastest market for Tissue
Sealants. Asia-Pacific and Rest of World are expected to gain market shares while the US may lose market
dominance.
The medical organizations all over the world have been persistently making efforts to manage wounds.
Medical practitioners have been trying to find an impeccable remedy substance that would seal and heal
human tissues and which would also be an ideal alternative to stick the tissue exteriors so that bleeding can
be prevented and also provide a supportive healing platform.
The latest arrivals in periodical development of wound management devices are the Fibrin sealants. They
are grouped differently as medical devices or pharmaceutical products as their distinctive characteristics
are to seal and heal tissues by blocking air and fluids from tissues and to render a strong basis for the
tissues to start healing.
Fibrin sealants can be used in post surgical methods for sealing the tissues which will help in the gain of
speedy recovery. They have such an in-built capacity to even eliminate the customary methods. Now days,
these Fibrin sealants are being used as supplements to wound closing procedures like sutures and staples.
Fibrin sealants may be autologous, i.e., developed from plasma of patient’s blood or pooled i.e., from many
donors. The risk of blood contamination and viral transmission scares imposes a decline in the growth of
such products . Research and Development are given least priority as they are cost intensive and risk areas,
as a result the market is still in its infancy with least rates of product development and technological
advancements.

Analysis by Source
The global market for homologous Sealants is the largest with a market of US$ XX.XX million in 2020.. In
terms of market value, Homologous Sealants was estimated at US$ XX.XX billion in 2012. Autologous
Sealants grew at a faster rate with a CAGR of XX.XX %.
Exhibit 4. Tissue Sealants – Global Value Market Estimations & Predictions (2005 -2020) by Source for
Homologous Sealants, Synthetic Sealants and Autologous Sealants in US$ Million
Year/Source Homologous Sealants Synthetic Sealants Autologous Sealants Total
2005 XX.XX XX.XX XX.XX XX.XX
CAGR% XX.XX XX.XX XX.XX XX.XX
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
US$ Million
HomologousSealants SyntheticSealants AutologousSealants

Exhibit 5. List of Major Companies in North America
S. No Company Name Country Website
1 3M Company USA www.3m.com
2 Abbott Laboratories USA www.abbott.com
6 Angiotech Pharmaceuticals, Inc. Canada www.angiotech.com
7 Baxter International, Inc. USA www.baxter.com
8 C.R. Bard, Inc. USA www.crbard.com
9 CryoLife, Inc. USA www.cryolife.com
10 CSL Behring USA www.cslbehring.com
11 Ethicon, Inc. USA www.ethiconinc.com
12 Kensey Nash Corporation USA www.kenseynash.com
13 King Pharmaceuticals, Inc. USA www.kingpharm.com
14 Medafor, Inc. USA www.medafor.com
15 Pfizer, Inc. USA www.pfizer.com
16 Protein Polymer Technologies, Inc. USA www.ppti.com
17 ThermoGenesis Corporation USA www.thermogenesis.com
© RIT, 2013

IV. PRODUCT TECHNOLOGY/ RESEARCH
At times, during surgery or other medical emergencies, major blood vessels are ruptured. Surgical methods
such as staples and sutures become essential for controlling such bleeding. In the meanwhile, however,
there is a possibility of losing substantial blood through unchecked bleeding. To mitigate such loss of blood,
a hemostat is used.
Hemostat stops the bleeding, and this process of checking bleeding is known as hemostasis. In natural
course, hemostasis starts almost immediately after a tissue is damaged. The process is completed in
phases.
The first phase involves restricting the blood to the region through vasoconstriction. In other words, there
is constriction of blood vascular system, which controls the blood supply to this region. This is the reason
this phase is known as vascular phase.
The broken endothelium of the vascular system at the site exposes collagen, which attracts platelets. The
platelets start the clotting as soon as they come in contact with blood. This is the second phase. A clot
retraction and clot destruction phase follows the second phase. In the clot destruction phase, plasminogen
is transformed into plasmin. This plasmin is responsible for clot lysis.
Amicar is a chemical agent that restricts the transformation of plasminogen into plasmin. Therefore, when
Amicar is administered, clots do not lyse and thereby become stable.
Clotting process or clotting cascade is made of two different pathways eventually joining together to form a
common pathway. One of these pathways is intrinsic and the other is the extrinsic.
The process of clotting is started by collagen, which when exposed, binds factor XII. Simultaneously
collagen also grabs platelets that are then activated by many other cofactors. As a result, platelets also
release different factors. Collectively, this pathway is known as intrinsic pathway.
The extrinsic pathway of clotting process is started by a tissue factor. This factor is exposed because of
tissue injury. This results in factor VII activation that starts this pathway. Both intrinsic and extrinsic
pathways of clotting combine to form a common route in which thrombin transforms fibrinogen into fibrin
monomers. These fibrin monomers are cross‐linked with calcium and factor XIII, forming fiber polymer,
which is the clot.
Because hemostats play such a crucial role in human life, they are indispensable in any first aid gear of
paramedics and combat doctors. Conventionally, a hemostatic clamp is used for stopping profuse bleeding
at outdoor locations. Hemostatic clamp restricts the bleeding by a mechanical action. This clamp is very
effective when a major artery is ruptured and blood starts gushing out.
During surgery, however, doctors use another type of hemostat. This hemostat is known as microfibrillar
collagen hemostat or MCH. MCH is made from resorbable microfibrillar collagen. This hemostat is generally
used when the bleeding is not from a major blood vessel. For controlling bleeding from major vessels,
hemostatic clamp is the best option even today.
MCH has a very specific mechanism in stopping the bleeding. Platelets are drawn towards MCH by chemical
interaction. This results in a blood clot as soon as the blood nears the MCH. There is no mechanical action

involved here. Surgeons apply MCH at the bleeding point and collagen does the rest.
The haemostatic effect of fibrin was first illustrated by Bergel in the 20th century. He explained the
hypothesis of employing clotting constituents from human blood for handling wounds and to arrive at
haemostatis in bleeding parenchymatous organs.
Surgical Sealants and their Significance
Hemostasis or clotting of blood is a natural physiological phenomenon of the body that prevents blood loss.
It involves a cascade of reaction steps. When the tissues are damaged by a cut, the blood platelets are
activated. These platelets convert inactive prothrombin of blood into active thrombin. The latter
transforms soluble blood protein fibrinogen into insoluble fibrin. The fibrin threads are viscous polymers,
which crosslink with activated blood factor XIII to form a mesh at the site of wound that prevents oozing of
blood. This mesh in which the erythrocytes get entangled is the clot. This clot is later on dissolved by the
enzyme fibrinolysin. Fibrinolysis involves the release of fibrinopeptides initiating angiogenesis [formation of
blood vessels] and tissue repair. The surgical sealants accelerate this process of hemostasis.
TISSUE SEALANTS – MARKET OUTLOOK
The market is already occupied by biological glues and adhesives which are strong synthetic and biological
materials that glue the surfaces together, preventing the wide spread use of fibrin sealants. Product
substitution and off label use are the areas challenging the wide spread use of fibrin sealants. Although the
market is aware about the advantages of fibrin sealants in cardiothoracic and pulmonary applications, their
utility in surgical applications is challenged because of insufficient clinical proof.
There will be an increasing market if there is enough documentation on the evidences collected for the use
of fibrin sealants in other areas of surgical applications
The policy of companies to improve the market is to invest more in new product development and new
areas of application which expands the market opportunities. In order to increase consumption of tissue
sealants, the consumer can be exposed to events imparting knowledge on the strengths, deviations and
commercial benefits of tissue sealants as compared to the other synthetic sealing devices. It will also help
subdue the issues of interchange owing to ill-defined differentiation amongst the diverse range of wound
care brands.
Scope for maximum tissue sealant applications (licensed indications) exist in Dental, Cardiac surgery,
pulmonary surgery and vascular surgery. There is an ascending perception in the use of tissue sealants in
hepatic surgery. Even though the needs for sealants in burn applications are bent to multiply, more
investigations are being done in orthopedic indications.
The current Pharmaco economic data is efficient in convincing the medical practitioners about versatility,
superiority and cost advantage of tissue sealants over challenging alternatives……………..
About RI Technologies

RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector. We
emphasize on factual insights and forecasts with maximum global coverage. RI Technologies is constantly
monitoring the biotechnology & Healthcare industry, tracking market trends, and forecasting industry
based on specialized analysis. The life sciences sector is an ever growing marketplace with emerging
technologies in areas of discovery, design and development.
Research – As Good as the Methodology is!
 Gauging Competitive Intelligence
 Identifying Key Growth Areas and Opportunities
 Understanding Geographic Relevance to Product
 Knowing Regional Market Sizes and Growth Opportunities and Restraints
 Keeping Tab on Emerging Technologies
 Equity Analysis
 Tapping New Markets
© COPYRIGHT
The copyright and publication rights to all RI Technologies' reports and other products are the property of
the company. Plagiarism of any kind accounts to violation of copyright laws. Any type of reproduction of
the material without express permission is not allowed. The buyer, under no circumstances, shall license,
resell or repackage, or sell data without prior permission of the company.
DISCLAIMER
RI Technologies sells content in good faith. The company is not liable to the buyer for any implications
arising out of the usage of data for any particular purpose. The company makes no representations or
warranties for the accuracy or completeness of the data. While extreme caution and effort is practiced for
data compilation and presentation, the company does not accept any responsibility for findings in the study
which are a cumulative effort of primary and secondary research resources. The studies do not endorse or
promote any product or company. RI Technologies, its affiliates, partners, distributors, and contractors are
not liable for inaccuracies or incompleteness of the reports. User discretion is recommended for the usage
of the data.

Tissue sealants market research report

Recomendados

Recomendados

Más contenido relacionado

Más de Research Impact

Más de Research Impact (14)

Último

Último (20)

Tissue sealants market research report